Trials / Terminated
TerminatedNCT02842021
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 283 (actual)
- Sponsor
- Sol-Gel Technologies, Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform power calculations for the Phase 3 pivotal trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S2G6T-1 | Twice a day topical cream |
| DRUG | S2G6T-2 | Twice a day topical cream |
| DRUG | S2G6T-3 | Twice a day topical cream |
| DRUG | S2G6T-4 | Twice a day topical cream |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2016-07-22
- Last updated
- 2020-11-18
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02842021. Inclusion in this directory is not an endorsement.